Clinical Formulation Supplies
Sai Life Sciences provides clinical formulation development and GMP manufacturing support for early-phase studies. We design and deliver clinical trial drug products that meet global quality standards, supporting progression from development into the clinic. Our capabilities span formulation optimization, GMP manufacturing, analytical testing, stability studies, packaging, labelling, and regulatory documentation—ensuring consistent, compliant, and on-time clinical supply.
Sai Life Sciences supports Phase I through Phase IIa clinical programs with fully GMP-compliant operations and coordinated execution across drug substance, analytical, and CMC teams.
Our Capabilities
GMP Clinical Manufacturing
Dedicated facilities for small- and mid-scale manufacturing of clinical trial supplies (CTS).
Formulation Optimization
Process and composition refinement to ensure scalable and reproducible formulations.
Analytical & Stability Testing
In-house analytical method validation, release testing, and stability studies.
Regulatory & CMC Documentation
Preparation of technical documentation to support global regulatory submissions.
Our Capabilities
GMP Clinical Manufacturing
Dedicated facilities for small- and mid-scale manufacturing of clinical trial supplies (CTS).
Formulation Optimization
Process and composition refinement to ensure scalable and reproducible formulations.
Analytical & Stability Testing
In-house analytical method validation, release testing, and stability studies.
Regulatory & CMC Documentation
Preparation of technical documentation to support global regulatory submissions.
Facilities & Technical Capabilities
- GMP processing suites for oral solid dosage forms, including:
- Uncoated tablets
- Film-coated tablets
- Enteric-coated tablets
- Capsules
- Modular GMP manufacturing environments
- Contained processing areas for potent compounds
- In-house analytical laboratories
- Validated quality and documentation systems
Automated systems and controlled environments support traceability, regulatory compliance, and reliable batch execution across clinical programs.
Frequently Asked Questions
Yes. GMP-compliant clinical formulations are manufactured for Phase I and Phase IIa programs. Coordinated alignment across drug substance, formulation, analytical, and manufacturing teams supports timely batch release and study initiation.
Batch consistency is maintained through validated GMP processes, in-process controls, comprehensive analytical testing, and stability monitoring. Quality systems and process oversight ensure reproducibility and regulatory compliance.
A structured, risk-based bridging strategy aligns preclinical and clinical requirements early in development. Physicochemical properties, stability, and bioavailability considerations inform scalable formulation design, minimizing reformulation risk during clinical transition.
Yes. Dedicated containment infrastructure, engineering controls, and validated safety protocols support development and manufacturing of highly potent and cytotoxic compounds while ensuring operator protection and product integrity.
Clinical batch sizes of up to 10,000 units are supported, depending on dosage form and protocol requirements.